Encouraging Price Action on SIRT

After rallying sharply and immediately on the positive SRT501 clinical data on January 8th, SIRT shares subsequently relinquished most of its gains. However, as the market has had time to digest the SRT501 data and the implications of potential future value, the subsequent price action has been very encouraging, given the weak overall markets:



Sirtuin Investor believes that SIRT could easily move towards the upper teens ($17-$19)within the next two weeks as institutional interest increases. Importantly, based on the low volume observed during this rise, the advent of irrational exuberance is still a way off (see SI BLOG 12/17/07).

Do your own due diligence and remember the SI proverb: immortality is expensive.